Thiol-disulfide exchanges modulate aldo-keto reductase family 1 member B10 activity and sensitivity to inhibitors

Biochimie

Volumn 92, Issue 5, 2010, Pages 530-537

  Shen, Yi ^a   Zhong, Linlin ^a,b   Markwell, Stephen ^a   Cao, D ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aldo keto reductase family 1 member B10; Aldose reductase inhibitors; Cysteine; Glutathione; Reactive oxygen species; Thiol disulfide exchanges

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER B10; ANTIOXIDANT; CYSTEINE; DISULFIDE; ENZYME; EPALRESTAT; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; THIOL; THIOL GROUP; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; OXIDATION; THIOL DISULFIDE EXCHANGE;

ALCOHOL OXIDOREDUCTASES; DISULFIDES; ENZYME INHIBITORS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS;

EID: 77951022483     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.02.001     Document Type: Article

References (45)

1. Cao D., Fan S.T., Chung S.S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 1998, 273:11429-11435.
2. Scuric Z., Stain S.C., Anderson W.F., Hwang J.J. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998, 27:943-950.
3. Hyndman D.J., Flynn T.G. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta 1998, 1399:198-202.
4. Fukumoto S., Yamauchi N., Moriguchi H., Hippo Y., Watanabe A., Shibahara J., Taniguchi H., Ishikawa S., Ito H., Yamamoto S., Iwanari H., Hironaka M., Ishikawa Y., Niki T., Sohara Y., Kodama T., Nishimura M., Fukayama M., Dosaka-Akita H., Aburatani H. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 2005, 11:1776-1785.
5. Zhong L., Liu Z., Yan R., Johnson S., Zhao Y., Fang X., Cao D. Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem. Biophys. Res. Commun. 2009.
6. Zu X., Yan R., Robbins S., Krishack P.A., Liao D.F., Cao D. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol. Sci. 2007, 97:562-568.
7. Ma J., Yan R., Zu X., Cheng J.M., Rao K., Liao D.F., Cao D. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J. Biol. Chem. 2008, 283:3418-3423.
8. Yan R., Zu X., Ma J., Liu Z., Adeyanju M., Cao D. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int. J. Cancer 2007, 121:2301-2306.
9. Wang C., Yan R., Luo D., Watabe K., Liao D.F., Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 2009.
10. Balendiran G.K., Martin H.J., El-Hawari Y., Maser E. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem. Biol. Interact. 2009, 178:134-137.
11. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., Maser E. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 2006, 34:464-470.
12. Quinn A.M., Harvey R.G., Penning T.M. Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 2008, 21:2207-2215.
13. Gallego O., Ruiz F.X., Ardevol A., Dominguez M., Alvarez R., de Lera A.R., Rovira C., Farres J., Fita I., Pares X. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. U S A 2007, 104:20764-20769.
14. Crosas B., Hyndman D.J., Gallego O., Martras S., Pares X., Flynn T.G., Farres J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 2003, 373:973-979.
15. Halliwell B. Oxidants and human disease: some new concepts. FASEB. J. 1987, 1:358-364.
16. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.
17. Oliver C.N., Ahn B.W., Moerman E.J., Goldstein S., Stadtman E.R. Age-related changes in oxidized proteins. J. Biol. Chem. 1987, 262:5488-5491.
18. Adelman R., Saul R.L., Ames B.N. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc. Natl. Acad. Sci. U S A 1988, 85:2706-2708.
19. Weinberg F., Chandel N.S. Reactive oxygen species-dependent signaling regulates cancer. Cell. Mol. Life Sci. 2009.
20. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell. Biochem. 2008, 104:657-667.
21. Heffner J.E., Repine J.E. Pulmonary strategies of antioxidant defense. Am. Rev. Respir. Dis. 1989, 140:531-554.
22. van Asbeck B.S., Hoidal J., Vercellotti G.M., Schwartz B.A., Moldow C.F., Jacob H.S. Protection against lethal hyperoxia by tracheal insufflation of erythrocytes: role of red cell glutathione. Science 1985, 227:756-759.
23. Cappiello M., Vilardo P.G., Micheli V., Jacomelli G., Banditelli S., Leverenz V., Giblin F.J., Corso A.D., Mura U. Thiol disulfide exchange modulates the activity of aldose reductase in intact bovine lens as a response to oxidative stress. Exp. Eye Res. 2000, 70:795-803.
24. Del Corso A., Vilardo P.G., Cappiello M., Cecconi I., Dal Monte M., Barsacchi D., Mura U. Physiological thiols as promoters of glutathione oxidation and modifying agents in protein S-thiolation. Arch. Biochem. Biophys. 2002, 397:392-398.
25. Riemer J., Bulleid N., Herrmann J.M. Disulfide formation in the ER and mitochondria: two solutions to a common process. Science 2009, 324:1284-1287.
26. Iciek M., Wlodek L. Biosynthesis and biological properties of compounds containing highly reactive, reduced sulfane sulfur. Pol. J. Pharmacol. 2001, 53:215-225.
27. Ladenstein R., Ren B. Protein disulfides and protein disulfide oxidoreductases in hyperthermophiles. FEBS J. 2006, 273:4170-4185.
28. Annis I., Hargittai B., Barany G. Disulfide bond formation in peptides. Methods Enzymol. 1997, 289:198-221.
29. Cappiello M., Voltarelli M., Cecconi I., Vilardo P.G., Dal Monte M., Marini I., Del Corso A., Wilson D.K., Quiocho F.A., Petrash J.M., Mura U. Specifically targeted modification of human aldose reductase by physiological disulfides. J. Biol. Chem. 1996, 271:33539-33544.
30. Verma M., Martin H.J., Haq W., O'Connor T.R., Maser E., Balendiran G.K. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur. J. Pharmacol. 2008, 584:213-221.
31. Chung S., LaMendola J. Cloning and sequence determination of human placental aldose reductase gene. J. Biol. Chem. 1989, 264:14775-14777.
32. Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., Shichiri M., Toyota T., Nakashima M., Yoshimura I., Sakamoto N., Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 2006, 29:1538-1544.
33. Ramirez M.A., Borja N.L. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008, 28:646-655.
34. Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin. Investig. Drugs 2008, 17:575-581.
35. Bril V., Hirose T., Tomioka S., Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009.
36. Hotta N., Sakamoto N., Shigeta Y., Kikkawa R., Goto Y. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic neuropathy study group in Japan. J. Diabetes Complicat. 1996, 10:168-172.
37. Richmond R., Halliwell B., Chauhan J., Darbre A. Superoxide-dependent formation of hydroxyl radicals: detection of hydroxyl radicals by the hydroxylation of aromatic compounds. Anal. Biochem. 1981, 118:328-335.
38. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
39. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 1968, 25:192-205.
40. Petrash J.M., Harter T.M., Devine C.S., Olins P.O., Bhatnagar A., Liu S., Srivastava S.K. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303. J. Biol. Chem. 1992, 267:24833-24840.
41. Harrison D.H., Bohren K.M., Petsko G.A., Ringe D., Gabbay K.H. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry 1997, 36:16134-16140.
42. 2 exposure on lens morphology and biochemistry. Exp. Eye Res. 1993, 57:157-167.
43. 2 induced cataract in rat lenses: distributions and effect of aging. Curr. Eye Res. 1995, 14:951-958.
44. Giannessi M., Del Corso A., Cappiello M., Voltarelli M., Marini I., Barsacchi D., Garland D., Camici M., Mura U. Thiol-dependent metal-catalyzed oxidation of bovine lens aldose reductase. I. Studies on the modification process. Arch. Biochem. Biophys. 1993, 300:423-429.
45. Reischl E., Dafre A.L., Franco J.L., Wilhelm Filho D. Distribution, adaptation and physiological meaning of thiols from vertebrate hemoglobins. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 146:22-53.